Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124973753 | 12497375 | 3 | F | 20160406 | 20160825 | 20160624 | 20160901 | EXP | GB-MHRA-ADR 23481241 | GB-MYLANLABS-2016M1024940 | MYLAN | 0.00 | Y | 0.00000 | 20160901 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124973753 | 12497375 | 1 | PS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | UNK | U | U | 75817 | |||||||||
| 124973753 | 12497375 | 2 | SS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | 120 MG, QD (6 WEEK COURSE ENDED AFTER 32 DAYS^5SA23(12/16) 5SA74(01/17) 5SF52(03/17) 5SL64(08/17) 5) | 2520 | MG | Y | U | 5SK16 | 0 | 120 | MG | QD | ||
| 124973753 | 12497375 | 3 | C | ADCAL D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | UNK | U | 0 | ||||||||||
| 124973753 | 12497375 | 4 | C | LETROZOLE. | LETROZOLE | 1 | UNK | U | 0 | ||||||||||
| 124973753 | 12497375 | 5 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | UNK | U | 0 | ||||||||||
| 124973753 | 12497375 | 6 | C | ZOMORPH | MORPHINE SULFATE | 1 | UNK | U | 0 | ||||||||||
| 124973753 | 12497375 | 7 | C | PERJETA | PERTUZUMAB | 1 | UNK | U | 0 | ||||||||||
| 124973753 | 12497375 | 8 | C | HERCEPTIN | TRASTUZUMAB | 1 | 1 DF, Q3W (ONGOING) | U | 0 | 1 | DF | QOW | |||||||
| 124973753 | 12497375 | 9 | C | PERTUZUMAB | PERTUZUMAB | 1 | 1 DF, Q3W (ONGOING ) | U | 0 | 1 | DF | QOW | |||||||
| 124973753 | 12497375 | 10 | C | DENOSUMAB | DENOSUMAB | 1 | 1 DF, EVERY 6 WEEKS | U | 0 | 1 | DF | ||||||||
| 124973753 | 12497375 | 11 | C | DOCETAXEL. | DOCETAXEL | 1 | UNK | U | 0 | ||||||||||
| 124973753 | 12497375 | 12 | C | DIURETIC /00022001/ | HYDROCHLOROTHIAZIDE | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124973753 | 12497375 | 1 | Antibiotic therapy |
| 124973753 | 12497375 | 2 | Peripheral embolism |
| 124973753 | 12497375 | 8 | Breast cancer stage IV |
| 124973753 | 12497375 | 9 | Breast cancer stage IV |
| 124973753 | 12497375 | 10 | Bone disorder |
| 124973753 | 12497375 | 11 | Breast cancer stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124973753 | 12497375 | OT |
| 124973753 | 12497375 | LT |
| 124973753 | 12497375 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124973753 | 12497375 | Blister | |
| 124973753 | 12497375 | Burning sensation | |
| 124973753 | 12497375 | Dermatitis | |
| 124973753 | 12497375 | Erythema multiforme | |
| 124973753 | 12497375 | Pain | |
| 124973753 | 12497375 | Protein deficiency | |
| 124973753 | 12497375 | Rash erythematous | |
| 124973753 | 12497375 | Scab | |
| 124973753 | 12497375 | Skin erosion | |
| 124973753 | 12497375 | Skin haemorrhage | |
| 124973753 | 12497375 | Tachycardia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124973753 | 12497375 | 2 | 20160317 | 20160417 | 0 | |
| 124973753 | 12497375 | 3 | 20151016 | 0 | ||
| 124973753 | 12497375 | 11 | 20160210 | 0 |